Responses to treatment
| Patient no. . | Effect of HDC/PBSC . | Follow-up duration, mo . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical response . | Complications . | Platelet count, K/mm3 . | Antiplatelet GP titer ratios . | DAT . | ||||||
| Before . | After 9-12 mo3-150 . | GP . | Before . | After . | Before . | After . | ||||
| 002 | CR | Vaginal bleeding; bacteremia (Staphylococcus epidermidis) | 20 | 250 | Ib | 0.5 | 1.0 | ND | ND | 41 |
| IIIa | 1.4 | 1.0 | ||||||||
| 005 | CR | GI and vaginal bleeding; bacteremia (S epidermidis, enterococcus); CMV reactivation | 9 | 183 | Ib | 0.4 | 1.6 | Pos | Neg | 14 (died of multiple myeloma) |
| IIIa | 0.1 | 1.2 | ||||||||
| 008 | CR | Bacteremia (Streptococcus mitis) | 5 | 233 | Ib | 2.3 | 4.2 | Pos | NI3-151 | 27 |
| IIIa | 6.3 | 1.8 | ||||||||
| 010 | CR | 3 | 151 | Ib | 5.2 | 1.3 | Pos | ND | 23 | |
| IIIa | 0.6 | 2.0 | ||||||||
| 013 | CR | Bacteremia (S epidermidis) | 1 | 344 | Ib | 0.6 | 1.5 | Pos | Neg | 9 |
| IIIa | 1.2 | 1.1 | ||||||||
| 014 | CR | Epistaxis | 6 | 315 | Ib | 16.1 | 15.6 | Neg | ND | 9 |
| IIIa | 2.1 | 1.4 | ||||||||
| 007 | PR | Bacteremia (S epidermidis); aspergillus pneumonitis 9 mo after transplantation | 3 | 60 | Ib | 5.7 | 5.4 | Neg | Neg | 19 (died of catheter-related sepsis) |
| IIIa | 2.3 | 8.2 | ||||||||
| 011 | PR | Bacteremia (S epidermidis) | 8 | 144 | Ib | 1.4 | 0.7 | Neg | Neg | 20 |
| IIIa | 0.6 | 0.7 | ||||||||
| 001 | NR | Hemorrhagic cystitis | 7 | 7 | Ib | 3.4 | 3.9 | Neg | ND | 42 |
| IIIa | 11.1 | 7.9 | ||||||||
| 003 | NR | 10 | 8 | Ib | 1.3 | 1.0 | Neg | Neg | 39 | |
| IIIa | 1.1 | 0.1 | ||||||||
| 004 | NR | 18 | 25 | Ib | 1.7 | 2.0 | ND | ND | 39 | |
| IIIa | 0.9 | 1.7 | ||||||||
| 006 | NR | 16 | 11 | Ib | 2.6 | 2.6 | Neg | ND | 30 | |
| IIIa | 3.7 | 0.6 | ||||||||
| 009 | NR | Bacteremia (S mitis) | 4 | 19 | Ib | 11.4 | 6.7 | Pos | Pos | 24 |
| IIIa | 16 | 8.4 | ||||||||
| 012 | NR | Bacteremia (S mitis) | 10 | 37 | Ib | 2.0 | 0.4 | Pos | Pos | 18 |
| IIIa | 29.6 | 30.0 | ||||||||
| Patient no. . | Effect of HDC/PBSC . | Follow-up duration, mo . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical response . | Complications . | Platelet count, K/mm3 . | Antiplatelet GP titer ratios . | DAT . | ||||||
| Before . | After 9-12 mo3-150 . | GP . | Before . | After . | Before . | After . | ||||
| 002 | CR | Vaginal bleeding; bacteremia (Staphylococcus epidermidis) | 20 | 250 | Ib | 0.5 | 1.0 | ND | ND | 41 |
| IIIa | 1.4 | 1.0 | ||||||||
| 005 | CR | GI and vaginal bleeding; bacteremia (S epidermidis, enterococcus); CMV reactivation | 9 | 183 | Ib | 0.4 | 1.6 | Pos | Neg | 14 (died of multiple myeloma) |
| IIIa | 0.1 | 1.2 | ||||||||
| 008 | CR | Bacteremia (Streptococcus mitis) | 5 | 233 | Ib | 2.3 | 4.2 | Pos | NI3-151 | 27 |
| IIIa | 6.3 | 1.8 | ||||||||
| 010 | CR | 3 | 151 | Ib | 5.2 | 1.3 | Pos | ND | 23 | |
| IIIa | 0.6 | 2.0 | ||||||||
| 013 | CR | Bacteremia (S epidermidis) | 1 | 344 | Ib | 0.6 | 1.5 | Pos | Neg | 9 |
| IIIa | 1.2 | 1.1 | ||||||||
| 014 | CR | Epistaxis | 6 | 315 | Ib | 16.1 | 15.6 | Neg | ND | 9 |
| IIIa | 2.1 | 1.4 | ||||||||
| 007 | PR | Bacteremia (S epidermidis); aspergillus pneumonitis 9 mo after transplantation | 3 | 60 | Ib | 5.7 | 5.4 | Neg | Neg | 19 (died of catheter-related sepsis) |
| IIIa | 2.3 | 8.2 | ||||||||
| 011 | PR | Bacteremia (S epidermidis) | 8 | 144 | Ib | 1.4 | 0.7 | Neg | Neg | 20 |
| IIIa | 0.6 | 0.7 | ||||||||
| 001 | NR | Hemorrhagic cystitis | 7 | 7 | Ib | 3.4 | 3.9 | Neg | ND | 42 |
| IIIa | 11.1 | 7.9 | ||||||||
| 003 | NR | 10 | 8 | Ib | 1.3 | 1.0 | Neg | Neg | 39 | |
| IIIa | 1.1 | 0.1 | ||||||||
| 004 | NR | 18 | 25 | Ib | 1.7 | 2.0 | ND | ND | 39 | |
| IIIa | 0.9 | 1.7 | ||||||||
| 006 | NR | 16 | 11 | Ib | 2.6 | 2.6 | Neg | ND | 30 | |
| IIIa | 3.7 | 0.6 | ||||||||
| 009 | NR | Bacteremia (S mitis) | 4 | 19 | Ib | 11.4 | 6.7 | Pos | Pos | 24 |
| IIIa | 16 | 8.4 | ||||||||
| 012 | NR | Bacteremia (S mitis) | 10 | 37 | Ib | 2.0 | 0.4 | Pos | Pos | 18 |
| IIIa | 29.6 | 30.0 | ||||||||
HDC indicates high-dose cyclophosphamide; CR, complete response; ND, not done; GI, gastrointestinal; pos, positive; neg, negative; PR, partial response; and NR, no response.
For patients 4, 5, 6, and 8, platelet counts from 6- to 7-month time points are shown due to unavailability of data for 9 to 12 months.
Not interpretable due to positive agglutination with saline control.